Arthrosi Appoints John Leaman, M.D., to Its Board of Directors [Yahoo! Finance]
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout, today announced the appointment of John Leaman , M.D., to its Board as an Independent Board Director. Arthrosi Logo (PRNewsfoto/Arthrosi Therapeutics) "John brings more than a decade of experience in finance, M&A and corporate strategy, with a strong understanding of gout, and we are excited to welcome him to our Board of Directors," said Litain Yeh, Ph.D., Founder and CEO of Arthrosi Therapeutics. "We believe that his insights and guidance will be invaluable as we continue to advance our pivotal Phase 3 program for AR882 and position the Company as a leader in treating gout, including tophaceous gout patients." John H. Leaman , M.D. is currently the Chief Financial Officer at Cellarity. During his tenure, he has helped oversee the close of a large pharma partnership, as well as leading the Company's Series D crossover financing. Prior to joining Cellarity i
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at BTIG Research. They set a "buy" rating and a $42.00 price target on the stock.MarketBeat
- Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock, up previously from $41.00.MarketBeat
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.MarketBeat
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) was upgraded by analysts at Cantor Fitzgerald to a "hold" rating.MarketBeat
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 12/13/24 - Form S-3
- 12/13/24 - Form S-3
- 12/13/24 - Form S-3
- RNAC's page on the SEC website